10:01 AM EST - Innunoprecise Antibodies Ltd. : And LiteVax BV (Oss, the Netherlands ), today announced that they have initiated pre-clinical vaccine trials against SARS-CoV-2. Vaccine design was based on large sets of data obtained during the analysis of IPA's SARS-CoV-2 therapeutic programs. Using this information, ImmunoPrecise designed data-driven, well-defined SARS-CoV-2 spike protein variant vaccine candidates that were combined with a novel class of synthetic carbohydrate derivatives, designed to act as a vaccine adjuvant, with the final formulations aimed at high efficacy and low adverse effects. Innunoprecise Antibodies Ltd.
shares V.IPA are trading up $0.08 at $2.45.
